Retina

According to presentations at FLORetina ICOOR 2024 in Florence, Italy, data show promising early improvements in low luminance visual acuity, a key measure of visual function. A pivotal Phase 2/3 VISTA trial for laru-zova in XLRP is currently enrolling.

The Belgian B Corp company, founded in 2016, is partially owned by Rayner and distributed in over 20 European countries.

Clinicians must consider redefining the metrics and intention behind functional outcomes, according to experts from the European Association for the Study of Diabetic Eye Complications

Presentation closely resembled mitogen-activated extracellular signal-regulated kinase inhibitor–associated retinopathy

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used hair dyes.

The annual meeting brought fourth announcements and insights from companies in the retina care space

Ahead of this year's Floretina meeting and International Congress on OCT Angiography, En Face OCT and Advances in OCT (ICOOR), David Hutton of Ophthalmology Times spoke with Charles Wykoff, MD, PhD. At FLORetina ICOOR, he presented on a number of topics, including diabetic retinopathy—the subject of his conversation with the Eye Care Network.

The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports with an association between RVO and heart attack risk.

Dr Wykoff addressed the top three questions retina specialists have about retinal non-perfusion

EAB members from Ophthalmology Times Europe, Ophthalmology Times and Modern Retina are presenting in Florence

Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.

The Foundation has assembled a multidisciplinary team of leading scientists, researchers, and physicians from multiple institutions, all focused on accelerating convergent technologies.

Breakthrough technologies are raising the ceiling for functional visual outcomes

What to expect from 4 days in the Fortezza de Basso

EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates Duravyu’s efficacy, durability, and re-dosing every 6 months in both treatment-naïve and previously treated patients. Topline data is anticipated in 2026.

Prevent Blindness announces its fourth annual Geographic Atrophy Awareness Week, December 2 to 8, 2024. The organization offers free educational resources, including videos and guides, and supports GA patients through programs like Living Well With Low Vision.

Preclinical research highlights mRNA-based therapy's potential to inhibit scar tissue and abnormal blood vessel growth in proliferative vitreoretinopathy, addressing a critical unmet need in treatment.

While studies of obesity and tobacco and alcohol consumption showed that many chronic diseases are affected by the factors being studied, none had mentioned an effect on glaucoma progression.

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in personalized ophthalmic care.

OCU410ST is indicated for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa and cone-rod dystrophy 3 (CORD3)

Early results suggest participant diversity and novel measures will enable new, artificial intelligence-driven insights. As the study evolves, it could lead to significant advancements in understanding how environmental exposures contribute not only to diabetes but also to its complications, including those affecting eye health, such as diabetic retinopathy.

A study by a team of Chinese researchers highlights the potential of optical coherence tomography angiography (OCTA) in detecting retinal microvascular damage in renal hypertension patients. OCTA identifies reduced vascular density in key retinal regions, offering a noninvasive tool for early diagnosis and systemic disease management.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for oculoplastic procedures from August 2018 to November 2020.

Avant Technologies and Ainnova Tech have partnered to develop a low-cost retinal camera integrated with Ainnova’s Vision AI platform for early detection of ocular and systemic diseases. The technology will be marketed as a SaaS platform for primary care settings.